logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12773452 B1

PDFFull Text
Date of Patent:
Oct. 27, 2026

Filed:

May. 05, 2021

Compositions and methods for tcr reprogramming using cd70 specific fusion proteins

Applicant:

Tcr2 Therapeutics Inc., Cambridge, MA (US);

Inventors:

Robert Hofmeister, Scituate, MA (US);

Dario Gutierrez, Waltham, MA (US);

Andrew Collard, Boston, MA (US);

Jason Lajoie, Brighton, MA (US);

Vania E. Ashminova, North Billerica, MA (US);

Michael Lofgren, Watertown, MA (US);

Amy Watt, East Bridgewater, MA (US);

Derrick Mccarthy, Cambridge, MA (US);

Robert Tighe, Cambridge, MA (US);

Assignee:

TCR2 THERAPEUTICS INC., Cambridge, MA (US);

Attorney:

WILSON SONSINI GOODRICH & ROSATI

Primary Examiner:

Christopher M Babic

Assistant Examiner:

Hanan Isam Abuzeineh

Int. Cl.
CPC ...
A61K 40/32 (2025.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
A61K 40/32 (2025.01); A61K 40/11 (2025.01); A61K 40/4232 (2025.01); A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); A61K 2239/13 (2023.05); A61K 2239/21 (2023.05); A61K 2239/22 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C12N 2510/00 (2013.01);
Abstract

Provided herein are T cell receptor (TCR) fusion proteins (TFPs) comprising CD70 binding domains, T cells engineered to express one or more TFPs, antibodies that specifically bind CD70, and methods of use thereof for the treatment of diseases, including cancer.

Find Patent Forward Citations

Quick Actions:

Hofmeister, Robert. (2026). Compositions and methods for tcr reprogramming using cd70 specific fusion proteins (U.S. Patent No. 12773452). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12773452

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…